Enzon Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 73   

Articles published

ENZN 0.392 -0.001 (-0.25%)
price chart
Distress Signals Prevail for Shares of Enzon Pharmaceuticals Inc. (NASDAQ:ENZN)
Shares of Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) have been on a consistent downtrend as of late, causing concern for stock owners.
Cash And Short-Term Investments For Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN ...
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) began the annual period ended 2015-12-31 with cash of $34.562 millions. It had beginning cash of$34.562 millions for the quarter period ended 2015-12-31.
Enzon Pharmaceuticals Inc Stock Upgraded (ENZN)
Compared to other companies in the Biotechnology industry and the overall market, ENZON PHARMACEUTICALS INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
Enzon Pharmaceuticals Selling Well Below Likely Future Distributions
Enzon Pharmaceuticals (NASDAQ:ENZN), formerly a development-stage darling, is now a $17 million market cap cigar-butt, which receives royalties on several drugs.
Warning! Enzon Pharmaceuticals Is Definitely Going To $0
Finance profile for the company! Right off the bat, that doesn't give us a lot of confidence, now does it? Enzon Pharmaceuticals (NASDAQ:ENZN) used to be a research stage biotech firm, focusing on a technology known as PEGylation. PEGylation was used ...
ENZON PHARMACEUTICALS INCORPORATED (OTCMKTS:ENZN) Short Interest Decreased By ...
Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA.
Stock Displaying Signs of a Downtrend: Enzon Pharmaceuticals Inc. (NASDAQ:ENZN)
Shares of Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) have been on a consistent downtrend as of late, causing concern for stock owners.
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) Quarterly Dividend Was $-37.562 Millions
For the year closed 2015-12-31 Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) had beginning cash of $34.562 millions, and was $34.562 millions for the quarterly period ended 2015-12-31.
What Do Hedge Funds Think of Enzon Pharmaceuticals, Inc. (ENZN)?
Is Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) a healthy stock for your portfolio? The smart money is becoming more confident.
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) Holds $11.672 In Cash And Short-Term ...
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) beginning cash is $34.562 millions for the fiscal ended 2015-12-31. The figure for the quarter ended 2015-12-31 stood at $34.562 millions.